Research map: Ceralasertib Plus Durvalumab in Chinese Patients with Advanced Solid Tumors: A Nonrandomized Clinical Trial

Back to the article

Papers in this map

  1. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer · Scott Joseph Antonia · 2017 · 4654 citations · Cited by this paper
  2. Abemaciclib Persistence in Patients with HR+, HER2−, Node-Positive Early Breast Cancer: a Real-World Analysis · 2025 · Related
  3. Cancer incidence and mortality in China, 2022 · Bingfeng Han · 2024 · 2241 citations · Cited by this paper
  4. A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia · 2026 · Related
  5. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells · Hiro Sato · 2017 · 716 citations · Cited by this paper
  6. Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): An Aggressive Disease Course and Limitations for Personalized Oncology · 2026 · Related
  7. Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design · Jeffrey M. Skolnik · 2008 · 280 citations · Cited by this paper
  8. The Immuno-oncology-Induced Cytokine Release Syndrome Patient Diary: A Content-Valid, Patient-Reported Outcome Measure · 2025 · Related
  9. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma · Hailong Sheng · 2020 · 234 citations · Cited by this paper
  10. Expression of Prostate-Specific Membrane Antigen in Salivary Gland Tumors · 2025 · Related
  11. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell–dependent antitumor activity following radiation · Frank P. Vendetti · 2018 · 211 citations · Cited by this paper
  12. Application and Progress of Antibody-Drug Conjugates (ADCs) in the Treatment of Metastatic Triple-Negative Breast Cancer · 2025 · Related
  13. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment · Adil Parvez · 2023 · 211 citations · Cited by this paper
  14. Real-World Epidemiology, Clinical Characteristics and Outcomes of Women with Germline BRCA Mutation and Early Breast Cancer in China · 2025 · Related
  15. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand · Lin Mei · 2019 · 160 citations · Cited by this paper
  16. Cost-effectiveness of Nivolumab + Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer in England · 2025 · Related
  17. ATR inhibition potentiates ionizing radiation‐induced interferon response via cytosolic nucleic acid‐sensing pathways · Xu Feng · 2020 · 148 citations · Cited by this paper
  18. Qualitative Interviews on the Experience of Orally vs. Intramuscularly Administered Endocrine Therapy for Advanced Breast Cancer: Patient and Healthcare Provider Perspectives · 2025 · Related
  19. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial · Benjamin Besse · 2024 · 134 citations · Cited by this paper
  20. Patient and Physician Perspectives on Multiple Myeloma Data Presented at ASCO and EHA 2025: A Podcast · 2025 · Related
  21. Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. · Linlin Sun · 2018 · 125 citations · Cited by this paper
  22. Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer · Seung Tae Kim · 2021 · 82 citations · Cited by this paper
  23. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation · Magnus T. Dillon · 2023 · 55 citations · Cited by this paper
  24. A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade · Natalie Y.L. Ngoi · 2021 · 40 citations · Cited by this paper
  25. Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs · Tian Zhang · 2023 · 23 citations · Cited by this paper
  26. Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma · Matthew Krebs · 2018 · 9 citations · Cited by this paper
  27. Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients with locally advanced, unresectable, stage Ⅲ nsclc in china · Xiaotong Jiang · 2022 · 3 citations · Cited by this paper
  28. LBA1 Ceralasertib (C) + durvalumab (D) in patients (pts) with locally advanced (LA) or metastatic (m) NSCLC who progressed on or after anti-PD-(L)1 and platinum-based chemotherapy (CT): Results from LATIFY · B. Besse · 2026 · 2 citations · Cited by this paper
  29. Untitled · Cited by this paper
  30. Untitled · Cited by this paper
  31. Untitled · Cited by this paper
  32. Untitled · Cited by this paper
  33. Untitled · Cited by this paper

Source: OpenAlex (CC0)